These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 22432840)
1. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update. Ghosh RK; Ghosh SM Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840 [TBL] [Abstract][Full Text] [Related]
2. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Mohammadpour AH; Akhlaghi F Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137 [TBL] [Abstract][Full Text] [Related]
3. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288 [TBL] [Abstract][Full Text] [Related]
4. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Niesor EJ Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074 [TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Shinkai H Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899 [TBL] [Abstract][Full Text] [Related]
6. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
7. Future of cholesteryl ester transfer protein inhibitors. Rader DJ; deGoma EM Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575 [TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Shinkai H Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630 [TBL] [Abstract][Full Text] [Related]
9. The end of the road for CETP inhibitors after torcetrapib? Joy T; Hegele RA Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058 [TBL] [Abstract][Full Text] [Related]
10. Dalcetrapib: a review of Phase II data. Robinson JG Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364 [TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Filippatos TD; Klouras E; Barkas F; Elisaf M Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534 [TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Barter P; Rye KA Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?]. Murín J; Pernický M; Kiňová S Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865 [TBL] [Abstract][Full Text] [Related]
14. Dalcetrapib , a cholesteryl ester transfer protein modulator. Hooper AJ; Burnett JR Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099 [TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344 [TBL] [Abstract][Full Text] [Related]
17. JTT-705: is there still future for a CETP inhibitor after torcetrapib? Rennings AJ; Stalenhoef A Expert Opin Investig Drugs; 2008 Oct; 17(10):1589-97. PubMed ID: 18808319 [TBL] [Abstract][Full Text] [Related]